Inventor · disambiguated record
George Kenneth Lloyd
Also filed as: LLOYD GEORGE KENNETH
12 granted patents·6 pending applications·164 citations·filing 2005–2025
91Inventor score
Files withBEYONDSPRING PHARMACEUTICALS INC13NEREUS PHARMACEUTICALS INC2PALLADINO MICHAEL2PALLADINO MICHAEL A1
Top patents by PatentIndex Score
18 records- 0198US7919497B2Analogs of dehydrophenylahistins and their therapeutic useNEREUS PHARMACEUTICALS INC·Filed 2006·Granted Apr 5, 2011·78 cites·6 claims
- 0294US8247552B2Analogs of dehydrophenylahistins and their therapeutic usePALLADINO MICHAEL·Filed 2011·Granted Aug 21, 2012·15 cites·12 claims
- 0393US7935704B2Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereofNEREUS PHARMACEUTICALS INC·Filed 2005·Granted May 3, 2011·20 cites·7 claims
- 0492US11229642B2Composition and method for reducing neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2017·Granted Jan 25, 2022·6 cites·25 claims
- 0592US10912748B2Compositions containing tucaresol or its analogsBEYONDSPRING PHARMACEUTICALS INC·Filed 2017·Granted Feb 9, 2021·8 cites·18 claims
- 0691US11857522B2Compositions containing tucaresol or its analogsBEYONDSPRING PHARMACEUTICALS INC·Filed 2021·Granted Jan 2, 2024·2 cites·26 claims
- 0791US8129527B2Analogs of dehydrophenylahistins and their therapeutic usePALLADINO MICHAEL A·Filed 2007·Granted Mar 6, 2012·15 cites·1 claims
- 0888US11786523B2Composition and method for reducing thrombocytopeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Granted Oct 17, 2023·3 cites·31 claims
- 0988US8618292B2Analogs of dehydrophenylahistins and their therapeutic usePALLADINO MICHAEL·Filed 2012·Granted Dec 31, 2013·12 cites·13 claims
- 1086US11400086B2Method of reducing chemotherapy-induced neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Granted Aug 2, 2022·5 cites·19 claims
- 1175US12458638B2Method of stimulating neutrophil survival and reducing neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Granted Nov 4, 2025·0 cites·21 claims
- 1268US2025375440A1Composition and method of treating cancer associated with egfr mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1367US12433886B2Composition and method for reducing neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Granted Oct 7, 2025·0 cites·19 claims
- 1463US2025152473A1Stable plinabulin formulations and methods of their preparation and useBEYONDSPRING PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1558US2024408082A1Methods for treating cancers and tumorsBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1652US2021161888A1Composition and method of treating cancer associated with egfr mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1744US2021030843A1Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agentBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1843US2020129504A1Compositions of plinabulin and use thereofBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →